Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
lefradafiban
Known as:
5-((((4'-(imino(methoxycarbonyl)amino)methyl)(1,1'-biphenyl)-4-yl)oxy)methyl)-2-oxo-pyrrolidineacetic acid, methyl ester
National Institutes of Health
Create Alert
Related topics
Related topics
2 relations
Broader (2)
Biphenyl Compounds
Pyrrolidines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Platelet Glycoprotein IIb / IIIa Receptor Inhibitors – Role in Coronary Artery Disease
N. Neki
2004
Corpus ID: 49530564
Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation…
Expand
2001
2001
Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist
N. Nicholson
,
N. Abood
,
+7 authors
R. J. Anders
Medicinal research reviews
2001
Corpus ID: 40728661
A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes…
Expand
2001
2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
K. M. Akkerhuis
,
M. J. van den Brand
,
+8 authors
M. Simoons
Heart
2001
Corpus ID: 9498420
OBJECTIVE Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase…
Expand
2000
2000
Absorption of lefradafiban from different sites of the gastrointestinal tract.
J. Drewe
,
H. Narjes
,
G. Heinzel
,
R. Brickl
,
A. Rohr
,
C. Beglinger
British journal of clinical pharmacology
2000
Corpus ID: 24519870
AIMS Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal…
Expand
2000
2000
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
K. M. Akkerhuis
,
K. Neuhaus
,
+9 authors
M. Simoons
European heart journal
2000
Corpus ID: 17644622
AIMS Oral glycoprotein IIb/IIIa inhibitors might enhance the early benefit of an intravenous agent and prevent subsequent cardiac…
Expand
1999
1999
A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
R. Storey
,
J. May
,
R. Wilcox
,
S. Heptinstall
Thrombosis and haemostasis
1999
Corpus ID: 40779417
We have used a whole blood single-platelet counting assay (WB-SPC) that is sensitive to microaggregation for monitoring GPIIb…
Expand
1999
1999
Lefradafiban. BIBU 104, BIBU 104XX.
Drugs in R&D
1999
Corpus ID: 12469367
Review
1998
Review
1998
Platelet inhibition: new agents, new strategies, new trials
D. Gulba
,
K. Huber
,
S. Moll
,
R. Dietz
1998
Corpus ID: 72709883
Summary Since platelet aggregation is dependent on the presence of functional GP IIb/IIIa receptors and since this receptor is…
Expand
Review
1998
Review
1998
Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
P. Chong
American journal of health-system pharmacy : AJHP…
1998
Corpus ID: 3113775
Recent studies of the effects of glycoprotein (GP) IIb/IIIa receptor antagonists on the clinical outcomes of patients with…
Expand
Highly Cited
1997
Highly Cited
1997
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
T. Mueller
,
H. Weisenberger
,
R. Brickl
,
H. Narjes
,
F. Himmelsbach
,
J. Krause
Circulation
1997
Corpus ID: 25770944
BACKGROUND Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE